Literature DB >> 29480208

A Genetic Study of Psychosis in Huntington's Disease: Evidence for the Involvement of Glutamate Signaling Pathways.

Debby W Tsuang1,2,3, Tiffany A Greenwood4, Suman Jayadev5, Marie Davis1,5, Andrew Shutes-David1,6, Thomas D Bird1,3,5.   

Abstract

BACKGROUND: Psychotic symptoms of delusions and hallucinations occur in about 5% of persons with Huntington's disease (HD). The mechanisms underlying these occurrences are unknown, but the same symptoms also occur in schizophrenia, and thus genetic risk factors for schizophrenia may be relevant to the development of psychosis in HD.
OBJECTIVE: To investigate the possible role of genes associated with schizophrenia in the occurrence of psychotic symptoms in HD.
METHODS: DNA from subjects with HD and psychosis (HD+P; n = 47), subjects with HD and no psychosis (HD-P; n = 126), and controls (CTLs; n = 207) was genotyped using the Infinium PsychArray-24 v1.1 BeadChip. The allele frequencies of single-nucleotide polymorphisms (SNPs) that were previously associated with schizophrenia and related psychiatric disorders were compared between these groups.
RESULTS: Of the 30 candidate genes tested, 10 showed an association with psychosis in HD. The majority of these genes, including CTNNA2, DRD2, ERBB4, GRID2, GRIK4, GRM1, NRG1, PCNT, RELN, and SLC1A2, demonstrate network interactions related to glutamate signaling.
CONCLUSIONS: This study suggests genetic associations between several previously identified candidate genes for schizophrenia and the occurrence of psychotic symptoms in HD. These data support the potential role of genes related to glutamate signaling in HD psychosis.

Entities:  

Keywords:  Delusions; Huntington disease; genetic association studies; genetic predisposition to disease; genetics; glutamates; hallucinations; modifier genes; psychotic disorders; schizophrenia

Mesh:

Substances:

Year:  2018        PMID: 29480208     DOI: 10.3233/JHD-170277

Source DB:  PubMed          Journal:  J Huntingtons Dis        ISSN: 1879-6397


  5 in total

Review 1.  Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels.

Authors:  Kasper B Hansen; Lonnie P Wollmuth; Derek Bowie; Hiro Furukawa; Frank S Menniti; Alexander I Sobolevsky; Geoffrey T Swanson; Sharon A Swanger; Ingo H Greger; Terunaga Nakagawa; Chris J McBain; Vasanthi Jayaraman; Chian-Ming Low; Mark L Dell'Acqua; Jeffrey S Diamond; Chad R Camp; Riley E Perszyk; Hongjie Yuan; Stephen F Traynelis
Journal:  Pharmacol Rev       Date:  2021-10       Impact factor: 18.923

Review 2.  Neurotransmitters-Key Factors in Neurological and Neurodegenerative Disorders of the Central Nervous System.

Authors:  Raluca Ioana Teleanu; Adelina-Gabriela Niculescu; Eugenia Roza; Oana Vladâcenco; Alexandru Mihai Grumezescu; Daniel Mihai Teleanu
Journal:  Int J Mol Sci       Date:  2022-05-25       Impact factor: 6.208

Review 3.  Involvement of extrasynaptic glutamate in physiological and pathophysiological changes of neuronal excitability.

Authors:  Balázs Pál
Journal:  Cell Mol Life Sci       Date:  2018-05-15       Impact factor: 9.261

4.  Acetylcholine receptor subunit expression in Huntington's disease mouse muscle.

Authors:  Briana Simpson; Mark M Rich; Andrew A Voss; Robert J Talmadge
Journal:  Biochem Biophys Rep       Date:  2021-12-05

5.  Genetic Risk Underlying Psychiatric and Cognitive Symptoms in Huntington's Disease.

Authors:  Natalie Ellis; Amelia Tee; Branduff McAllister; Thomas Massey; Duncan McLauchlan; Timothy Stone; Kevin Correia; Jacob Loupe; Kyung-Hee Kim; Douglas Barker; Eun Pyo Hong; Michael J Chao; Jeffrey D Long; Diane Lucente; Jean Paul G Vonsattel; Ricardo Mouro Pinto; Kawther Abu Elneel; Eliana Marisa Ramos; Jayalakshmi Srinidhi Mysore; Tammy Gillis; Vanessa C Wheeler; Christopher Medway; Lynsey Hall; Seung Kwak; Cristina Sampaio; Marc Ciosi; Alastair Maxwell; Afroditi Chatzi; Darren G Monckton; Michael Orth; G Bernhard Landwehrmeyer; Jane S Paulsen; Ira Shoulson; Richard H Myers; Erik van Duijn; Hugh Rickards; Marcy E MacDonald; Jong-Min Lee; James F Gusella; Lesley Jones; Peter Holmans
Journal:  Biol Psychiatry       Date:  2019-12-17       Impact factor: 12.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.